Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypersensitivity reactions from taxol.

R B Weiss1, R C Donehower, P H Wiernik

  • 1Department of Medicine, Walter Reed Army Medical Center, Washington, DC 20307.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|July 11, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Reply to letter to the editor 'Primum non nocere' by Templeton and Šeruga.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis.

Annals of oncology : official journal of the European Society for Medical Oncology·2014
Same author

Targeting basal-like breast cancers.

Current drug targets·2012
Same author

Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer.

British journal of cancer·2012

Hypersensitivity reactions (HSRs) to the antitumor drug Taxol occurred in 32 of 301 patients, often during initial exposures. These reactions, characterized by symptoms like dyspnea and rash, necessitate management guidelines.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Toxicology

Background:

  • Taxol (paclitaxel) is an investigational antitumor agent demonstrating efficacy against advanced ovarian carcinoma and melanoma.
  • Hypersensitivity reactions (HSRs) are a noted toxicity associated with Taxol administration during clinical trials.

Purpose of the Study:

  • To report the incidence and characteristics of hypersensitivity reactions (HSRs) observed in patients treated with Taxol.
  • To provide clinical guidelines for preventing, minimizing, and treating Taxol-induced HSRs.

Main Methods:

  • Retrospective analysis of 301 patients treated with Taxol.
  • Documentation of hypersensitivity reactions, including onset, symptoms, and patient history (e.g., premedication, infusion duration).

Related Experiment Videos

Main Results:

  • 32 out of 301 patients (10.6%) experienced definite or possible HSRs to Taxol.
  • Reactions predominantly occurred during the first or second drug exposure.
  • Common symptoms included dyspnea, hypotension, bronchospasm, urticaria, and erythematous rashes; premedication did not prevent HSRs in 41% of affected patients.
  • Prolonging infusion time reduced but did not eliminate HSR risk.

Conclusions:

  • Taxol-induced HSRs are a significant clinical concern, often occurring early in treatment.
  • The exact cause and mechanism of Taxol HSRs remain undetermined.
  • Clinical guidelines are necessary for managing Taxol-related hypersensitivity toxicity.